Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Connected with Pfizer Launching New Treatment

Lucy Kart

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Connected with Pfizer Launching New Treatment

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 1,282.14 Mn in 2022 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, life-threatening disease characterized by the buildup of abnormal deposits of misfolded transthyretin protein (amyloid) in the heart muscle. These amyloid deposits interfere with the normal functioning of the heart and may lead to heart failure or abnormal heart rhythms. Currently available treatments for ATTR-CM aim to slow or halt the progression of the disease. ATTR-CM treatment options include tafamidis, which act to stabilize the transthyretin protein. Improved diagnostic techniques are enabling earlier identification and treatment of ATTR-CM patients.

Market key trends:

One of the key trends in the ATTR-CM treatment market is the launch of new therapies by major players. In 2019, Pfizer launched Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for the treatment of ATTR-CM. These are the first and only approved therapies that specifically target transthyretin stabilization for the treatment of the disease. The approval and launch of new medications is expected to significantly drive the growth of the ATTR-CM treatment market over the forecast period. Currently several pharmaceutical companies are conducting trials for new product candidates to treat ATTR-CM. Positive results from ongoing late stage clinical trials can translate into regulatory approvals and subsequent launch of new therapies, further boosting the market.

Porter's Analysis

Threat of new entrants: Low, as there are several regulatory approvals and the market already has strong competitors with established distribution channels.

Bargaining power of buyers: Moderate, as there are few existing approved treatment options for ATTR-CM, buyers have some bargaining power.

Bargaining power of suppliers: Moderate, as the key technology suppliers have their proprietary technologies, buy the dependence on such suppliers is also high.

Threat of new substitutes: Moderate, as new alternative therapies for ATTR-CM are under clinical trials which can emerge as substitutes.

Competitive rivalry: High, as the major players are focusing on developing innovative therapies and target new geographical regions to stay ahead of competition.

Key Takeaways

The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing R&D investment in development of novel disease-modifying therapies.

North America is expected to dominate the global ATTR-CM treatment market during the forecast period. This is attributed to growing diagnosis rate of ATTR-CM, strong presence of key market players, and favorable reimbursement scenario in the region. However, Asia Pacific is anticipated to exhibit the fastest growth rate over the coming years owing to increasing healthcare spending and rising awareness about hereditary ATTR amyloidosis in major Asian countries.

Key players operating in the ATTR-CM treatment market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. Major companies are focused on conducting clinical trials to develop disease-modifying therapies with improved safety and efficacy profiles.

Explore More- https://www.trendingwebwire.com/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-market-size-and-growth-analysis/

Lucy Kart

Transthyretin Amyloid Cardiomyopathy Treatment Market is driven by Increasing Prevalence of ATTR-CM Disease

Sneha 2024-02-29

The global transthyretin amyloid cardiomyopathy treatment market is primarily driven by the increasing prevalence of ATTR-CM disease globally. Key TakeawaysKey players operating in the transthyretin amyloid cardiomyopathy treatment market are DermaSweep Inc. Impact of the current geopolitical situation on the Transthyretin Amyloid Cardiomyopathy Treatment Market growthThe ongoing geopolitical tensions and conflicts around the world are posing challenges for the growth of the Transthyretin Amyloid Cardiomyopathy Treatment market. Impact of geographical regions on the Transthyretin Amyloid Cardiomyopathy Treatment MarketNorth America currently accounts for the largest share of the global Transthyretin Amyloid Cardiomyopathy Treatment market in terms of value. Geographical region witnessing fastest growth in the Transthyretin Amyloid Cardiomyopathy Treatment MarketThe Asia Pacific region is poised to witness the fastest growth in the global Transthyretin Amyloid Cardiomyopathy Treatment market during the forecast period.

Transthyretin Amyloid Cardiomyopathy Treatment: Giving Hope to Patients Through Research

Leena Shedmake 2024-03-26

However, due to significant medical advancements in recent times, ATTR-CM patients now have real hope for managing their disease and improving outcomes. The rise of disease-modifying therapiesTill recently, Transthyretin Amyloid Cardiomyopathy Treatment options for ATTR-CM were limited to medications that only managed symptoms. Several clinical studies have demonstrated their ability to improve cardiac parameters and quality of life in ATTR-CM patients. Longer follow up studies are evaluating if this gene therapy approach can halt or reverse cardiac amyloid deposits. Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment

Living with Familial Amyloid Cardiomyopathy: Coping Strategies and Support Resources

Steve martin 2023-04-24

The heart is impacted by FAC, a rare genetic disorder that can have an influence on everyday living and quality of life. Maintaining an open and honest communication with medical professionals about symptoms, available treatments, and long-term care planning is a crucial coping technique. Resources for support are also beneficial for patients and families dealing with as familial amyloid cardiomyopathy (FAC). People who have had similar experiences might feel connected and understood by one another through support groups and internet forums. For individuals and families impacted with FAC, patient advocacy organisations provide resources and assistance, such as the Amyloidosis Foundation.

leg swelling treatment near torrance

OfficeWebmaster353 2022-01-12

leg swelling treatment near torranceOur Services Venous Procedures Varicose veins are large engorged veins that can feel like rope or cords under your skin. They can cause itching. Read More 3-D Echocardiography A 3-D ultrasound transducer (wand-like apparatus) is placed on the chest to produce the clearest image of the heart. cardiofitla. com

Several companies are working to develop effective treatments for familial amyloid cardiomyopathy.

CMI Blogging 2021-09-20

Chemotherapy treatments, cardiac medications, targeted therapies, organ transplant, dialysis, and autologous blood stem cell transplant are all utilized to treat amyloidosis.

Amyloid light chain amyloidosis, autoimmune amyloidosis, familial amyloidosis, wide-type (or senile) amyloidosis, dialysis-related, and cardiac amyloidosis are the most prevalent forms of amyloidosis.

The aggregation and deposition of mutant and wild-type transthyretin (TTR) protein in the heart characterizes familial amyloid cardiomyopathy (FAC) or transthyretin amyloid cardiomyopathy (ATTR-CM).

FAC may have an impact on how electrical signals go through the heart (conduction system).

Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive results from a Phase 3b open-label study to evaluate the safety, efficacy, and pharmacokinetics of patisiran in patients with hereditary ATTR (hATTR) amyloidosis who progressed to polyneuropathy after receiving an orthotopic liver transplant in June 2021.

Inotersen is a 2-MOE antisense oligonucleotide drug that reduces the quantity of mutant and normal TTR produced by the liver.

Hypertrophic Cardiomyopathy Treatment Market Size, Trends, Analysis And Forecast 2023-2032

Bhuvan 2023-12-15

The Hypertrophic Cardiomyopathy Treatment Global Market Report 2023 evaluates hypertrophic cardiomyopathy treatment market size, growth rate, drivers, trends, and major companies. id=13017&type=smpThe global hypertrophic cardiomyopathy treatment market is expected to grow from $1. The hypertrophic cardiomyopathy treatment market size is expected to see steady growth in the next few years. The increase in obesity is expected to propel the growth of the hypertrophic cardiomyopathy treatment market going forward. Get More Information On The Hypertrophic Cardiomyopathy Treatment Market Report:https://www.

WHO TO FOLLOW